

C-BRIGHT DARK SPOT CORRECTOR

Brighter-looking skin, measured over eight weeks.

Standardized photography and ImagePro analysis documented a progressive facial-brightness story, with favorable Week 8 results across brightness, hyperpigmentation, and the appearance of dark marks following acne.



- 34 women
- 8 weeks
- Standardized photography
- ImagePro analysis
- Tested as SGF22003-00 / IK101521A

5.0%
mean improvement in facial brightness
 WEEK 8
 ImagePro chroma analysis, n=34; p<0.001.

88%
of participants improved in brightness
 WEEK 8
 ImagePro analysis, n=34.

77%
improved in dark marks following acne
 WEEK 8
 Targeted subgroup, n=13; p=0.016.

VISIBLE RESULTS

A complexion that looked progressively brighter with continued use.

Facial brightness - mean improvement 5.0%




Week 8, n=34; p<0.001.

Hyperpigmentation appearance - mean improvement 2.5%




Week 8 subgroup, n=21; p=0.021.

Dark marks following acne - mean improvement 1.2%



Week 8 subgroup, n=13; p=0.016.

L* lightening effect - mean improvement 0.3%



Week 8, n=34; p=0.041.

MEASUREMENT-FIRST EVIDENCE

A trained technician captured standardized facial images at Baseline and Weeks 2, 4, and 8. ImagePro software provided instrument-based measurement of four appearance endpoints.

76%

of the hyperpigmentation subpanel improved at Week 8.

85%

of the full panel moved favorably on the L* endpoint at Week 8.

HOW TO READ THE RESULTS

Mean improvement describes the average measured change. "Participants improved" describes how many individuals moved in the favorable direction. Both are shown without blending them.

TECHNICAL STUDY RECORD

Independent photographic evidence, presented with its full endpoint context.

INDEPENDENT LABORATORY Essex Testing Clinic	STUDY IDENTIFIER ETC Panel 23049
TESTED ARTICLE C-Bright Dark Spot Correcting Serum SGF22003-00 / IK101521A	DESIGN 8-week single-arm baseline comparison
POPULATION 34 women completed	EVIDENCE METHOD Standardized photography + ImagePro analysis
VISITS Baseline, Week 2, Week 4, Week 8	SOURCE RECORD Essex Panel 23049 Topline Summary

Complete ImagePro time course

Endpoint	Timepoint	Mean ± SD	Mean change	Improved	p-value
Hyperpigmentation (n=21)	Baseline	91.7 ± 31.7	-	-	-
Hyperpigmentation	Week 2	91.3 ± 31.4	-0.4%	43%	0.627
Hyperpigmentation	Week 4	94.1 ± 32.2	+2.6%	76%	0.005
Hyperpigmentation	Week 8	94.0 ± 31.5	+2.5%	76%	0.021
Dark acne-scar appearance (n=13)	Baseline	182.7 ± 9.1	-	-	-
Dark acne-scar appearance	Week 2	183.3 ± 9.3	+0.3%	62%	0.346
Dark acne-scar appearance	Week 4	182.1 ± 9.6	-0.3%	38%	0.428
Dark acne-scar appearance	Week 8	184.9 ± 10.2	+1.2%	77%	0.016
Facial brightness (n=34)	Baseline	26.2 ± 6.9	-	-	-
Facial brightness	Week 2	26.2 ± 6.8	0.0%	50%	0.780
Facial brightness	Week 4	26.8 ± 7.1	+2.3%	76%	0.001
Facial brightness	Week 8	27.5 ± 6.8	+5.0%	88%	<0.001
L* lightening endpoint (n=34)	Baseline	77.2 ± 6.0	-	-	-
L* lightening endpoint	Week 2	77.2 ± 6.1	0.0%	47%	0.973
L* lightening endpoint	Week 4	77.0 ± 6.0	-0.3%	35%	0.130
L* lightening endpoint	Week 8	77.4 ± 5.8	+0.3%	85%	0.041

Increase was defined as improvement by the source. Hyperpigmentation used Subjects 1-21; dark acne-scar appearance used Subjects 22-34; brightness and L* used all 34 participants.

STUDY APPLICATION

Results apply to C-Bright Dark Spot Correcting Serum SGF22003-00 / IK101521A under the reported eight-week study design.

Cosmetic appearance findings apply to the tested article, participants, endpoints, and timepoints. Individual results may vary.



INDEPENDENT LABORATORY EVIDENCE

Original source pages follow.

The complete two-page Essex topline is reproduced next, preserving the laboratory letterhead, endpoint tables, and Quality Assurance notice.

LABORATORY Essex Testing Clinic	PANEL 23049
TEST ARTICLE SGF22003-00 / IK101521A	PAGES REPRODUCED Complete two-page topline

SOURCE AUTHENTICATION

The reproduced Essex pages retain the original laboratory letterhead, Panel 23049 identification, tested-article identifiers, endpoint tables, and Quality Assurance notice.

Independent laboratory source pages are included in the complete PDF. Participant-identifying information has been removed where indicated; aggregate findings are unchanged.

ETC Panel No. 23049 – Topline Summary

The information contained in this topline summary has undergone preliminary review by Quality Assurance. However, no significant changes are expected following final QA review.

Test Article: C-Bright Dark Spot Correcting Serum SGF22003-00 / IK101521A

A total of 34 female subjects were enrolled and completed the study.

► Hyperpigmentation – Image Analysis (Subjects 1-21)

At baseline and after 2, 4 and 8 weeks of product use, a trained technician took digital images of the face of each subject. Using ImagePro® software, the images were analyzed to determine changes in the appearance of hyperpigmentation. An increase in the skin saturation score represented an improvement of skin color.

The following table presents a summary of hyperpigmentation image analysis.

Hyperpigmentation – Image Analysis
Mean Score ± Standard Deviation (S.D.), Mean Change from Baseline and % of Subjects with Improvement from Baseline

	Mean Score ± S.D.	p-value	Mean Change from Baseline	% of Subjects with Improvement from Baseline
Baseline	91.7 ± 31.7	-	-	-
2 Weeks	91.3 ± 31.4	0.627	-0.4%	43%
4 Weeks	94.1* ± 32.2	0.005	2.6%	76%
8 Weeks	94.0* ± 31.5	0.021	2.5%	76%

*Statistically significant difference from baseline, $p \leq 0.05$

When images after 2, 4 and 8 weeks of product use were compared with baseline images, there was a mean worsening of 0.4% and mean improvements of 2.6% and 2.5%, respectively, based on image analysis. The change after 2 weeks was not statistically significant. The improvements after 4 and 8 weeks of product use were statistically significant compared with baseline. A total of 43%, 76% and 76% of the subjects showed improvement after 2, 4 and 8 weeks of product use, respectively.

► Dark Acne Scars – Image Analysis (Subjects 22-34)

At baseline and after 2, 4 and 8 weeks of product use, a trained technician took digital images of the face of each subject. Using ImagePro® software, the images were analyzed to determine changes in the appearance of dark acne scars. An increase in the value score indicates an improvement.

The following table presents a summary of dark acne scars image analysis.

Dark Acne Scars – Image Analysis
Mean Score ± Standard Deviation (S.D.), Mean Change from Baseline and % of Subjects with Improvement from Baseline

	Mean Score ± S.D.	p-value	Mean Change from Baseline	% of Subjects with Improvement from Baseline
Baseline	182.7 ± 9.1	-	-	-
2 Weeks	183.3 ± 9.3	0.346	0.3%	62%
4 Weeks	182.1 ± 9.6	0.428	-0.3%	38%
8 Weeks	184.9* ± 10.2	0.016	1.2%	77%

*Statistically significant difference from baseline, $p \leq 0.05$

When images after 2, 4 and 8 weeks of product use were compared with baseline images, there were mean improvements of 0.3% and 1.2% and a mean worsening of 0.3%, respectively, based on image analysis. The improvement after 2 weeks and change after 4 weeks were not statistically significant. The improvement after 8 weeks of product use was statistically significant compared with baseline. A total of 62%, 38% and 77% of the subjects showed improvement after 2, 4 and 8 weeks of product use, respectively.

ETC Panel No. 23049 – Topline Summary

The information contained in this topline summary has undergone preliminary review by Quality Assurance. However, no significant changes are expected following final QA review.

Test Article: C-Bright Dark Spot Correcting Serum SGF22003-00 / IK101521A

► Skin Brightness Evaluation

At baseline and after 2, 4 and 8 weeks of product use, a trained technician took digital images of the face of each subject. Using ImagePro® software, the images were analyzed to determine changes in the appearance of skin brightness. An increase in the chroma score represents an improvement in skin brightness.

The following table presents a summary of skin brightness image analysis.

**Facial Skin Brightness Evaluation – Image Analysis
Mean Score ± S.D., Mean Change from Baseline
and % of Subjects with Improvement from Baseline**

	Mean Score ± S.D.	p-value	Mean Change from Baseline	% of Subjects with Improvement from Baseline
Baseline	26.2 ± 6.9	-	-	-
2 Weeks	26.2 ± 6.8	0.780	0%	50%
4 Weeks	26.8* ± 7.1	0.001	2.3%	76%
8 Weeks	27.5* ± 6.8	<0.001	5.0%	88%

*Statistically significant difference from baseline, p≤0.05

When images after 2, 4 and 8 weeks of product use were compared with baseline images, there were mean improvements of 2.3% and 5.0%, respectively, based on image analysis. There was no change after 2 weeks of product use which was not statistically significant compared with baseline. The improvements after 4 and 8 weeks were statistically significant. A total of 50%, 76% and 88% of the subjects showed improvement after 2, 4 and 8 weeks of product use, respectively.

► Skin Tone Evaluation

At baseline and after 2, 4 and 8 weeks of product use, a trained technician took digital images of the face of each subject. Using ImagePro® software, the images were analyzed to determine changes in the appearance of skin tone. An increase in the L* value indicated an improvement (a lightening effect).

The following table presents a summary of skin tone image analysis.

**Facial Skin Tone Evaluation – Image Analysis
Mean Score ± S.D., Mean Change from Baseline
and % of Subjects with Improvement from Baseline**

	Mean Score ± S.D.	p-value	Mean Change from Baseline	% of Subjects with Improvement from Baseline
Baseline	77.2 ± 6.0	-	-	-
2 Weeks	77.2 ± 6.1	0.973	0%	47%
4 Weeks	77.0 ± 6.0	0.130	-0.3%	35%
8 Weeks	77.4* ± 5.8	0.041	0.3%	85%

*Statistically significant difference from baseline, p≤0.05

When images after 2, 4 and 8 weeks of product use were compared with baseline images, there was a mean worsening of 0.3% and mean improvement of 0.3%, respectively, based on image analysis. There was no change after 2 weeks of product use which was not statistically significant compared with baseline. The change after 4 weeks was not statistically significant. The improvement after 8 weeks was statistically significant. A total of 47%, 35% and 85% of the subjects showed improvement after 2, 4 and 8 weeks of product use, respectively.